Immunotherapy targeting the PD-1/PD-L1 has been successful in advanced cervical cancer, but the potential clinical value of other checkpoint molecules remains unknown, such as TIM-3/LGALS9 or HLA-G/ILT2. The gene discussed is LILRB1; the disease is cervical cancer.